The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines

Owari, Takuya; Iwamoto, Takashi; Anai, Satoshi; Miyake, Makito; Nakai, Yasushi; Hara, Takeshi; Ishii, Takuya; Ota, Urara; Torimoto, Kazumasa; Kuniyasu, Hiroki; Fujii, Tomomi; Tanaka, Nobumichi; Fujimoto, Kiyohide

doi:10.1016/j.pdpdt.2021.102309

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with a previous study [ 29 ], we found a considerable variation in the BBN-induced bladder cancer model, with up to a 15-week variation in tumorigenesis time. Therefore, BBN studies typically rely on detecting large tumor masses [ 30 ] or ex vivo fluorescence imaging [ 31 ]. The device presented in this study overcame this significant limitation of BBN-based tumor studies by enabling the minimally invasive yet sensitive detection of early tumor fluorescence.…”

Section: Discussionmentioning

confidence: 99%

Fluorescence-Based Microendoscopic Sensing System for Minimally Invasive In Vivo Bladder Cancer Diagnosis

Lee

Cho

et al. 2022

Biosensors

View full text Add to dashboard Cite

Bladder cancer is commonly diagnosed by evaluating the tissue morphology through cystoscopy, and tumor resection is used as the primary treatment approach. However, these methods are limited by lesion site specificity and resection margin, and can thereby fail to detect cancer lesions at early stages. Nevertheless, rapid diagnosis without biopsy may be possible through fluorescence sensing. Herein, we describe a minimally invasive imaging system capable of sensing even small tumors through a 1.2 mm diameter flexible fiber bundle microprobe. We demonstrate that this new device can be used for the early diagnosis of bladder cancer in rats. Bladder cancer was induced in rats using the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN), and a togglable filter capable of PpIX fluorescence sensing was installed in the microendoscopic system. Following 5-aminolevulinic acid administration, tissue in the early stages of bladder cancer was successfully identified with fluorescence detection and confirmed with hematoxylin/eosin and ferrochelatase staining. Although the time required for BBN to induce bladder cancer varied between 3 and 4 weeks among the rats, the microendoscopic system allowed the minimally invasive follow-up on cancer development.

show abstract

Section: Discussionmentioning

confidence: 99%

Fluorescence-Based Microendoscopic Sensing System for Minimally Invasive In Vivo Bladder Cancer Diagnosis

Lee

Cho

et al. 2022

Biosensors

View full text Add to dashboard Cite

show abstract

“…As its name implies, PDD utilizes fluorescent PS agents in order to identify tumor tissues. In PDD, a PS which is selective for the target tumor cells is utilized (Dobson et al, 2018;Kim and Wilson, 2020;Nompumelelo Simelane et al, 2020;Fukuhara et al, 2021;Luan et al, 2021;Owari et al, 2021). The PS can be excited with a light source at a specific wavelength.…”

Section: Photodynamic Diagnosismentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been used as an anti-tumor treatment method for a long time and photosensitizers (PS) can be used in various types of tumors. Originally, light is an effective tool that has been used in the treatment of diseases for ages. The effects of combination of specific dyes with light illumination was demonstrated at the beginning of 20th century and novel PDT approaches have been developed ever since. Main strategies of current studies are to reduce off-target effects and improve pharmacokinetic properties. Given the high interest and vast literature about the topic, approval of PDT as the first drug/device combination by the FDA should come as no surprise. PDT consists of two stages of treatment, combining light energy with a PS in order to destruct tumor cells after activation by light. In general, PDT has fewer side effects and toxicity than chemotherapy and/or radiotherapy. In addition to the purpose of treatment, several types of PSs can be used for diagnostic purposes for tumors. Such approaches are called photodynamic diagnosis (PDD). In this Review, we provide a general overview of the clinical applications of PDT in cancer, including the diagnostic and therapeutic approaches. Assessment of PDT therapeutic efficacy in the clinic will be discussed, since identifying predictors to determine the response to treatment is crucial. In addition, examples of PDT in various types of tumors will be discussed. Furthermore, combination of PDT with other therapy modalities such as chemotherapy, radiotherapy, surgery and immunotherapy will be emphasized, since such approaches seem to be promising in terms of enhancing effectiveness against tumor. The combination of PDT with other treatments may yield better results than by single treatments. Moreover, the utilization of lower doses in a combination therapy setting may cause less side effects and better results than single therapy. A better understanding of the effectiveness of PDT in a combination setting in the clinic as well as the optimization of such complex multimodal treatments may expand the clinical applications of PDT.

show abstract

“…Recently published experimental studies tried to evaluate the duration of this effect. Owari et al [17] performed repeated PDD at 0–8 h on carcinogen-induced bladder cancer orthotropic rat models after oral 5-ALA administration. Additionally, plasma and tissue concentrations of PpIX and 5-ALA were measured with high-performance liquid chromatography.…”

Section: Timing Of Hexaminolaevulinic Acid or 5-aminolaevulinic Acid ...mentioning

confidence: 99%

Transurethral resection of bladder cancer with or without fluorescence

Horňák

Brisuda

Babjuk

2023

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewTransurethral resection of bladder cancer (TURBT) is in its standard form an inherently imperfect technique. Fluorescence-guided photodynamic diagnosis (PDD) represents one way to improve the outcome by enhancing tumour detection. Fluorescence has been used in connection with bladder cancer since the 1970s, with a number of studies being published since then. However, the method is still not recommended as a standard part of TURBT mainly because of the limited level of evidence of concerned studies, questionable cost-effectiveness and even contradictory results. The review lists the latest articles covering this topic. Recent findingsSeveral recently published meta-analyses reviewed a series of randomized controlled trials (RCTs) concerning PDD assisted TURBT. Results were generally supporting the positive effect on reduction of recurrence rate. However, the mentioned meta-analyses are overlapping in terms of reviewed RCT that provide only a low level of evidence according to a recent Cochrane review. Supposed limitations of PDD (timing of the procedure, low specificity) and possible solutions are also covered.

show abstract

The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines

Cited by 7 publications

References 29 publications

Fluorescence-Based Microendoscopic Sensing System for Minimally Invasive In Vivo Bladder Cancer Diagnosis

Fluorescence-Based Microendoscopic Sensing System for Minimally Invasive In Vivo Bladder Cancer Diagnosis

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Transurethral resection of bladder cancer with or without fluorescence

Contact Info

Product

Resources

About